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Background
The majority of assays currently used to assess HIV-1
vaccine candidate immunogenicity in humans fail to
predict protection against HIV-1 acquisition or control
of viraemia. However, a correlation between in vivo and
ex vivo control mediated by CD8+ T-cell populations
has been described using an ex vivo virus inhibition
assay (VIA) in chronically infected individuals and vacci-
nated non-human primates. Here we attempt to relate
the specificity of vaccine-induced virus-specific CD8
responses to the inhibition of HIV-1 ex vivo.
Methods
Using peptide epitope mapping, we assessed the breadth
and specificity of CD8 T-cell responses induced by vacci-
nation using two adenovirus serotype 35 (Ad35) vectors
containing gag, reverse transcriptase, integrase and nef
(Ad35-GRIN) and env (Ad35-ENV), respectively, derived
from HIV-1 subtype A isolates. The conserved regions
targeted by these 25 subjects were related to the capacity
of vaccine-induced CD8 T-cells to inhibit replication of a
cross-clade panel of HIV-1 isolates using the VIA.
Results
A median of 4 peptides were recognised in vaccinated
individuals (range 1-9). When related to the log reduc-
tion of p24 production as measured in the VIA, mapping
data suggest that targeting immunodominant responses
towards highly conserved regions of the HIV-1 proteome
tended towards an increased ability to inhibit multiple
clades of HIV-1 ex vivo.
Conclusion
These data support the plausibility of inducing conserved
CD8+ T cell responses using a consensus HIV-1 subtype
A sequence in an adenovirus-based vector.
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